{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T09:50:50Z","timestamp":1790243450301,"version":"4.1.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T00:00:00Z","timestamp":1623369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T00:00:00Z","timestamp":1623369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Long-term effects of continuous subcutaneous apomorphine infusion (CSAI) on health-related quality of life (HRQoL) and predictors of CSAI discontinuation are poorly known. Data from consecutive advanced Parkinson\u2019s disease patients treated in routine care were retrospectively collected over 24 months after CSAI initiation, with a focus on the 39-item Parkinson\u2019s disease questionnaire (PDQ-39). We determined predictors of CSAI discontinuation and HRQoL improvement using multiple regression analysis. Of the 110 subjects evaluated over a 2-year period, 35% discontinued CSAI. Of those who continued treatment, HRQoL remained stable with a sustained reduction in motor fluctuations. The observed effect on dyskinesias was mild and transient. Of note, patients with preexisting impulse control disorders showed an overall good tolerability. PDQ-39 was the only baseline predictor of HRQoL improvement after 2 years of treatment. The presence of dyskinesias, poorer psychological status, shorter disease duration, male sex, and worse OFF state were predictors of discontinuation. Best candidates for CSAI are patients with: (i) poor baseline HRQoL and (ii) marked motor fluctuations.<\/jats:p>","DOI":"10.1038\/s41531-021-00194-7","type":"journal-article","created":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T10:05:00Z","timestamp":1623405900000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Long-term effect of apomorphine infusion in advanced Parkinson\u2019s disease: a real-life study"],"prefix":"10.1038","volume":"7","author":[{"given":"Bruna","family":"Meira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Degos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Corsetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Doulazmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emeline","family":"Berthelot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3951-4653","authenticated-orcid":false,"given":"Clara","family":"Virbel-Fleischman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Dodet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"M\u00e9neret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise-Laure","family":"Mariani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Delorme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Cormier-Dequaire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6310-1250","authenticated-orcid":false,"given":"David","family":"Bendetowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Villain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Tarrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise","family":"Mantisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Letrillart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Louapre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eavan","family":"McGovern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulia","family":"Worbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Grabli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Vidailhet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Hainque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9727-3459","authenticated-orcid":false,"given":"Emmanuel","family":"Roze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,11]]},"reference":[{"key":"194_CR1","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1002\/mds.27372","volume":"33","author":"SH Fox","year":"2018","unstructured":"Fox, S. H. et al. International Parkinson and Movement Disorder Society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson\u2019s disease. Mov. Disord. 33, 1248\u20131266 (2018).","journal-title":"Mov. Disord."},{"key":"194_CR2","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/mds.26125","volume":"30","author":"CC Aquino","year":"2015","unstructured":"Aquino, C. C. & Fox, S. H. Clinical spectrum of levodopa-induced complications. Mov. Disord. 30, 80\u201389 (2015).","journal-title":"Mov. Disord."},{"issue":"Suppl1","key":"194_CR3","doi-asserted-by":"publisher","first-page":"S123","DOI":"10.1016\/S1353-8020(11)70038-4","volume":"18","author":"MM Iravani","year":"2012","unstructured":"Iravani, M. M., McCreary, A. C. & Jenner, P. Striatal plasticity in Parkinson\u2019s disease and L-dopa induced dyskinesia. Parkinsonism Relat. Disord. 18(Suppl1), S123\u2013S125 (2012).","journal-title":"Parkinsonism Relat. Disord."},{"key":"194_CR4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00702-015-1418-0","volume":"123","author":"R Kr\u00fcger","year":"2016","unstructured":"Kr\u00fcger, R. et al. Advanced stages of PD: interventional therapies and related patient-centered care. J. Neural Transm. 123, 31\u201343 (2016).","journal-title":"J. Neural Transm."},{"key":"194_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-020-01062-2","volume":"20","author":"N Prakash","year":"2020","unstructured":"Prakash, N. & Simuni, T. Infusion therapies for Parkinson\u2019s disease. Curr. Neurol. Neurosci. Rep. 20, 44 (2020).","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"194_CR6","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s40261-018-0619-3","volume":"38","author":"M Auffret","year":"2018","unstructured":"Auffret, M., Drapier, S. & V\u00e9rin, M. Pharmacological insights into the use of apomorphine in Parkinson\u2019s disease: clinical relevance. Clin. Drug. Investig. 38, 287\u2013312 (2018).","journal-title":"Clin. Drug. Investig."},{"key":"194_CR7","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1002\/mds.870080208","volume":"8","author":"AJ Hughes","year":"1993","unstructured":"Hughes, A. J. et al. Subcutaneous apomorphine in Parkinson\u2019s disease: response to chronic administration for up to five years. Mov. Disord. 8, 165\u2013170 (1993).","journal-title":"Mov. Disord."},{"key":"194_CR8","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1002\/mds.22063","volume":"23","author":"PJ Garcia Ruiz","year":"2008","unstructured":"Garcia Ruiz, P. J. et al. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson\u2019s disease with motor fluctuations: a multicenter study. Mov. Disord. 23, 1130\u20131136 (2008).","journal-title":"Mov. Disord."},{"key":"194_CR9","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1007\/s00415-017-8477-0","volume":"264","author":"\u00c1 Sesar","year":"2017","unstructured":"Sesar, \u00c1., Fern\u00e1ndez-Pajar\u00edn, G., Ares, B., Rivas, M. T. & Castro, A. Continuous subcutaneous apomorphine infusion in advanced Parkinson\u2019s disease: 10-year experience with 230 patients. J. Neurol. 264, 946\u2013954 (2017).","journal-title":"J. Neurol."},{"key":"194_CR10","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.parkreldis.2013.08.012","volume":"19","author":"A Todorova","year":"2013","unstructured":"Todorova, A. & Chaudhuri, K. R. Subcutaneous apomorphine and non-motor symptoms in Parkinson\u2019s disease. Parkinsonism Relat. Disord. 19, 1073\u20131078 (2013).","journal-title":"Parkinsonism Relat. Disord."},{"key":"194_CR11","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3233\/JPD-2011-11037","volume":"1","author":"P Martinez-Martin","year":"2011","unstructured":"Martinez-Martin, P. et al. Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson\u2019s disease compared to conventional therapy: a real-life study of non-motor effect. J. Parkinson\u2019s Dis. 1, 197\u2013203 (2011).","journal-title":"J. Parkinson\u2019s Dis."},{"key":"194_CR12","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/mds.26067","volume":"30","author":"P Martinez-Martin","year":"2015","unstructured":"Martinez-Martin, P. et al. EuroInf: a multicentre comparative observational study of apomorphine and levodopa infusion in Parkinson\u2019s disease. Mov. Disord. 30, 510\u2013516 (2015).","journal-title":"Mov. Disord."},{"key":"194_CR13","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/mds.27626","volume":"34","author":"HS Dafsari","year":"2019","unstructured":"Dafsari, H. S. et al. EuroInf 2: subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson\u2019s disease. Mov. Disord. 34, 353\u2013365 (2019).","journal-title":"Mov. Disord."},{"key":"194_CR14","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/S1474-4422(18)30239-4","volume":"17","author":"R Katzenschlager","year":"2018","unstructured":"Katzenschlager, R. et al. Apomorphine subcutaneous infusion in patients with Parkinson\u2019s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 17, 749\u2013759 (2018).","journal-title":"Lancet Neurol."},{"key":"194_CR15","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s00415-016-8106-3","volume":"263","author":"S Drapier","year":"2016","unstructured":"Drapier, S. et al. Quality of life in Parkinson\u2019s disease improved by apomorphine pump: the OPTIPUMP cohort study. J. Neurol. 263, 1111\u20131119 (2016).","journal-title":"J. Neurol."},{"key":"194_CR16","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.jns.2016.11.080","volume":"372","author":"M Auffret","year":"2017","unstructured":"Auffret, M. et al. Apomorphine pump in advanced Parkinson\u2019s disease: effects on motor and nonmotor symptoms with brain metabolism correlations. J. Neurol. Sci. 372, 279\u2013287 (2017).","journal-title":"J. Neurol. Sci."},{"key":"194_CR17","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.neurol.2013.10.012","volume":"170","author":"M Rambour","year":"2014","unstructured":"Rambour, M. et al. [Continuous subcutaneous infusion of apomorphine in Parkinson\u2019s disease: retrospective analysis of a series of 81 patients]. Rev. Neurol. 170, 205\u2013215 (2014).","journal-title":"Rev. Neurol."},{"key":"194_CR18","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1097\/WNF.0000000000000361","volume":"42","author":"R Bhidayasiri","year":"2019","unstructured":"Bhidayasiri, R. et al. Long-term apomorphine infusion users versus short-term users: an international dual-center analysis of the reasons for discontinuing therapy. Clin. Neuropharmacol. 42, 172\u2013178 (2019).","journal-title":"Clin. Neuropharmacol."},{"key":"194_CR19","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1007\/s10072-019-03920-5","volume":"40","author":"E Olivola","year":"2019","unstructured":"Olivola, E. et al. Continuous subcutaneous apomorphine infusion in Parkinson\u2019s disease: causes of discontinuation and subsequent treatment strategies. Neurol. Sci. 40, 1917\u20131923 (2019).","journal-title":"Neurol. Sci."},{"key":"194_CR20","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1205158","volume":"368","author":"WM Schuepbach","year":"2013","unstructured":"Schuepbach, W. M. et al. Neurostimulation for Parkinson\u2019s disease with early motor complications. N. Engl. J. Med. 368, 610\u2013622 (2013).","journal-title":"N. Engl. J. Med."},{"key":"194_CR21","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3233\/JPD-191765","volume":"10","author":"C Cattane","year":"2020","unstructured":"Cattane, C., Jost, W. H. & Bonizzoni, E. Long-term efficacy of safinamide on symptoms severity and quality of life in fluctuating Parkinson\u2019s disease patients. J. Parkinson\u2019s Dis. 10, 89\u201397 (2020).","journal-title":"J. Parkinson\u2019s Dis."},{"key":"194_CR22","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1136\/jnnp.72.2.241","volume":"72","author":"J Marinus","year":"2002","unstructured":"Marinus, J., Ramaker, C., van Hilten, J. J. & Stiggelbout, A. Health related quality of life in Parkinson\u2019s disease: a systematic review of disease specific instruments. J. Neurol. Neurosurg. Psychiatry 72, 241\u2013248 (2002).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"194_CR23","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/mds.23462","volume":"26","author":"P Martinez-Martin","year":"2011","unstructured":"Martinez-Martin, P., Rodriguez-Blazquez, C., Kurtis, M. M., Chaudhuri, K. R. & Group, N. V. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson\u2019s disease. Mov. Disord. 26, 399\u2013406 (2011).","journal-title":"Mov. Disord."},{"key":"194_CR24","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.parkreldis.2019.05.009","volume":"65","author":"GD Kuhlman","year":"2019","unstructured":"Kuhlman, G. D., Flanigan, J. L., Sperling, S. A. & Barrett, M. J. Predictors of health-related quality of life in Parkinson\u2019s disease. Parkinsonism Relat. Disord. 65, 86\u201390 (2019).","journal-title":"Parkinsonism Relat. Disord."},{"key":"194_CR25","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/bs.irn.2017.05.023","volume":"133","author":"P Barone","year":"2017","unstructured":"Barone, P., Erro, R. & Picillo, M. Quality of life and nonmotor symptoms in Parkinson\u2019s disease. Int. Rev. Neurobiol. 133, 499\u2013516 (2017).","journal-title":"Int. Rev. Neurobiol."},{"key":"194_CR26","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.parkreldis.2015.06.012","volume":"21","author":"C Trenkwalder","year":"2015","unstructured":"Trenkwalder, C. et al. Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson\u2019s disease\u2014clinical practice recommendations. Parkinsonism Relat. Disord. 21, 1023\u20131030 (2015).","journal-title":"Parkinsonism Relat. Disord."},{"key":"194_CR27","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1136\/jnnp.54.4.372","volume":"54","author":"K Ray-Chaudhuri","year":"1991","unstructured":"Ray-Chaudhuri, K., Abbott, R. J. & Millac, P. A. Subcutaneous apomorphine for Parkinsonian patients with psychiatric side effects on oral treatment. J. Neurol. Neurosurg. Psychiatry 54, 372\u2013373 (1991).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"194_CR28","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S1353-8020(97)00009-6","volume":"3","author":"C Ellis","year":"1997","unstructured":"Ellis, C. et al. Use of apomorphine in Parkinsonian patients with neuropsychiatric complications to oral treatment. Parkinsonism Relat. Disord. 3, 103\u2013107 (1997).","journal-title":"Parkinsonism Relat. Disord."},{"key":"194_CR29","unstructured":"Todorova, A. et al. Assessment of impulse control disorders in Parkinson\u2019s patients with infusion therapies: a single center experience. Mov. Disord. 28(Suppl 1), 366 (2013)."},{"key":"194_CR30","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1097\/WNF.0000000000000091","volume":"38","author":"A Todorova","year":"2015","unstructured":"Todorova, A., Samuel, M., Brown, R. G. & Chaudhuri, K. R. Infusion therapies and development of impulse control disorders in advanced Parkinson disease: clinical experience after 3 years\u2019 follow-up. Clin. Neuropharmacol. 38, 132\u2013134 (2015).","journal-title":"Clin. Neuropharmacol."},{"key":"194_CR31","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/mdc3.12416","volume":"4","author":"P Barbosa","year":"2017","unstructured":"Barbosa, P., Lees, A. J., Magee, C., Djamshidian, A. & Warner, T. T. A retrospective evaluation of the frequency of impulsive compulsive behaviors in Parkinson\u2019s disease patients treated with continuous waking day apomorphine pumps. Mov. Disord. Clin. Pract. 4, 323\u2013328 (2017).","journal-title":"Mov. Disord. Clin. Pract."},{"key":"194_CR32","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1002\/mds.23072","volume":"25","author":"C Colosimo","year":"2010","unstructured":"Colosimo, C. et al. Task force report on scales to assess dyskinesia in Parkinson\u2019s disease: critique and recommendations. Mov. Disord. 25, 1131\u20131142 (2010).","journal-title":"Mov. Disord."},{"key":"194_CR33","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1136\/jnnp.64.5.573","volume":"64","author":"A Colzi","year":"1998","unstructured":"Colzi, A., Turner, K. & Lees, A. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson\u2019s disease. J. Neurol. Neurosurg. Psychiatry 64, 573\u2013576 (1998).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"194_CR34","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1002\/mds.10281","volume":"17","author":"AJ Alice J Manson","year":"2002","unstructured":"Alice J Manson, A. J., Turner, K. & Lees, A. J. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson\u2019s disease: long-term follow-up study of 64 patients. Mov. Disord. 17, 1235\u20131241 (2002).","journal-title":"Mov. Disord."},{"key":"194_CR35","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/mds.20276","volume":"20","author":"R Katzenschlager","year":"2005","unstructured":"Katzenschlager, R. et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson\u2019s disease: a prospective study using single-dose challenges. Mov. Disord. 20, 151\u2013157 (2005).","journal-title":"Mov. Disord."},{"issue":"Suppl 1","key":"194_CR36","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1016\/j.parkreldis.2016.12.003","volume":"33","author":"P Peter Jenner","year":"2016","unstructured":"Peter Jenner, P. & Katzenschlager, R. Apomorphine\u2014pharmacological properties and clinical trials in Parkinson\u2019s disease. Parkinsonism Relat. Disord. 33(Suppl 1), S13\u2013S21 (2016).","journal-title":"Parkinsonism Relat. Disord."},{"key":"194_CR37","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.parkreldis.2015.11.013","volume":"23","author":"RW Borgemeester","year":"2016","unstructured":"Borgemeester, R. W., Drent, M. & van Laar, T. Motor and non-motor outcomes of continuous apomorphine infusion in 125 Parkinson\u2019s disease patients. Parkinsonism Relat. Disord. 23, 17\u201322 (2016).","journal-title":"Parkinsonism Relat. Disord."},{"issue":"Suppl 1","key":"194_CR38","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.3233\/JPD-202104","volume":"10","author":"JM Dijk","year":"2020","unstructured":"Dijk, J. M., Espay, A. J., Katzenschlager, R. & de Bie, R. M. A. The choice between advanced therapies for parkinson\u2019s disease patients: why, what, and when? J. Parkinsons Dis. 10(Suppl 1), S65\u2013S73 (2020).","journal-title":"J. Parkinsons Dis."},{"key":"194_CR39","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/13548506.2018.1510131","volume":"24","author":"F Tramonti","year":"2019","unstructured":"Tramonti, F. et al. Caregiver burden and family functioning in different neurological diseases. Psychol. Health Med. 24, 27\u201334 (2019).","journal-title":"Psychol. Health Med."},{"key":"194_CR40","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S1353-8020(99)00012-7","volume":"5","author":"C McRae","year":"1999","unstructured":"McRae, C., Sherry, P. & Roper, K. Stress and family functioning among caregivers of persons with Parkinson\u2019s disease. Parkinsonism Relat. Disord. 5, 69\u201375 (1999).","journal-title":"Parkinsonism Relat. Disord."},{"key":"194_CR41","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/mdc3.12819","volume":"6","author":"C B\u00fcttner","year":"2019","unstructured":"B\u00fcttner, C., Maack, M., Janitzky, K. & Witt, K. The evolution of quality of life after subthalamic stimulation for Parkinson\u2019s disease: a meta-analysis. Mov. Disord. Clin. Pract. 6, 521\u2013530 (2019).","journal-title":"Mov. Disord. Clin. Pract."},{"key":"194_CR42","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.parkreldis.2017.09.018","volume":"45","author":"A Antonini","year":"2017","unstructured":"Antonini, A. et al. Levodopa-carbidopa intestinal gel in advanced Parkinson\u2019s: Final results of the GLORIA registry. Parkinsonism Relat. Disord. 45, 13\u201320 (2017).","journal-title":"Parkinsonism Relat. Disord."},{"key":"194_CR43","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1159\/000113714","volume":"5","author":"A Antonini","year":"2005","unstructured":"Antonini, A. et al. Duodenal levodopa infusion improves quality of life in advanced Parkinson\u2019s disease. Neurodegener. Dis. 5, 244\u2013246 (2005).","journal-title":"Neurodegener. Dis."},{"key":"194_CR44","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma, R. B. et al. MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov. Disord. 30, 1591\u20131601 (2015).","journal-title":"Mov. Disord."},{"key":"194_CR45","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1002\/mds.23429","volume":"25","author":"CL Tomlinson","year":"2010","unstructured":"Tomlinson, C. L. et al. Systematic review of levodopa dose equivalency reporting in Parkinson\u2019s disease. Mov. Disord. 25, 2649\u20132653 (2010).","journal-title":"Mov. Disord."},{"key":"194_CR46","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/ageing\/26.5.353","volume":"26","author":"C Jenkinson","year":"1997","unstructured":"Jenkinson, C., Fitzpatrick, R., Peto, V., Greenhall, R., & Hyman, N. The Parkinson\u2019s Disease Questionnaire (PDQ-39): development and validation of a Parkinson\u2019s disease summary index score. Age Ageing 26, 353\u2013357 (1997).","journal-title":"Age Ageing"},{"key":"194_CR47","unstructured":"Fahn, S., Elton, R. & Members of the UPDRS Development Committee. The unified Parkinson\u2019s disease rating scale. in Recent Developments in Parkinson\u2019s Disease Vol. 2 (eds Fahn, S., Marsden, C. D., Calne, D. B. & Goldstein, M.) 153\u2013163 (McMellam Health Care Information, 1987)."},{"key":"194_CR48","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1212\/WNL.17.5.427","volume":"17","author":"MM Hoehn","year":"1997","unstructured":"Hoehn, M. M. & Yahr, M. D. Parkinsonism: onset, progression and mortality. Neurology 17, 427\u2013442 (1997).","journal-title":"Neurology"},{"key":"194_CR49","unstructured":"Schwab, R. S. & England, A. C. Projection technique for evaluating surgery in Parkinson\u2019s disease. in Third Symposium on Parkinson\u2019s Disease (eds Billingham, F. H. and Donaldson, M. C.) 152\u2013157 (Churchill Livingstone, 1969)."},{"key":"194_CR50","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein, M. F., Folstein, S. E. & McHugh, P. R. Mini-mental state\u2019. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12, 189\u2013198 (1975).","journal-title":"J. Psychiatr. Res."},{"key":"194_CR51","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1212\/WNL.55.11.1621","volume":"55","author":"B Dubois","year":"2000","unstructured":"Dubois, B., Slachevsky, A., Litvan, I. & Pillon, B. The FAB: a frontal assessment battery at bedside. Neurology 55, 1621\u20131626 (2000).","journal-title":"Neurology"},{"key":"194_CR52","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.neurol.2009.06.003","volume":"165","author":"C Ardouin","year":"2009","unstructured":"Ardouin, C. et al. Assessment of hyper- and hypo-dopaminergic behaviors in Parkinson\u2019s disease. Rev. Neurol. 165, 845\u2013856 (2009).","journal-title":"Rev. Neurol."},{"key":"194_CR53","doi-asserted-by":"publisher","first-page":"e000994","DOI":"10.1136\/rmdopen-2019-000994","volume":"5","author":"D Mongin","year":"2019","unstructured":"Mongin, D. et al. Imputing missing data of function and disease activity in rheumatoid arthritis registers: what is the best technique? RMD Open 5, e000994 (2019).","journal-title":"RMD Open"},{"issue":"2","key":"194_CR54","doi-asserted-by":"publisher","first-page":"S130","DOI":"10.1016\/S1353-8020(09)70500-0","volume":"15","author":"Y Naidu","year":"2009","unstructured":"Naidu, Y. et al. Efficacy of apomorphine infusion on mood and depression aspects of non-motor symptoms in advanced Parkinson\u2019s disease. Parkinsonism Relat. Disord. 15(2), S130 (2009).","journal-title":"Parkinsonism Relat. Disord."}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-021-00194-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-021-00194-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-021-00194-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T21:52:27Z","timestamp":1670017947000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-021-00194-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,11]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["194"],"URL":"https:\/\/doi.org\/10.1038\/s41531-021-00194-7","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,11]]},"assertion":[{"value":"9 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.D. served on scientific advisory boards for Aguettant, received research support from Orkyn and Elivie, and received travel grant from Orkyn and Elivie; E.B. received travel grant from Vitalaire and PEPS; C.V.-F. received a grant from Association Nationale de la Recherche et de la Technologie and full-time employment by Air Liquide Healthcare; P.D. received a travel grant from UCB pharma; A.M. received travel funding from AbbVie and Merz; L.-L.M. received speech honoraria from Lundbeck and Teva and received travel funding from the Medtronic, Teva, and AbbVie; C.D. received travel grant from Medtronic and Boston Scientific; D.B. received travel grant from Boston Scientific; L.M. received a travel grant from Orkyn (Air Liquide), Abbvie, Elivie, and Medtronic; H.L. received a travel grant from Orkyn (Air Liquide), Abbvie, and Elivie; E.M. received travel grant from Elivie; D.G. served on scientific advisory boards for AbbVie and Zambon, received speech honoraria from Medtronic and Abbvie, received research support from Air Liquide, and received travel grant from Abbvie; E.H. served on scientific advisory boards for Medtronic and Boston Scientific, received honoraria for speeches from Boston Scientific, and received travel grant from Merz; E.R. served on scientific advisory boards for Orkyn and Aguettant, received honoraria for speeches from Orkyn, Aguettant, and EVER Pharma, received research support from Orkyn, Aguettant, Elivie, and EVER Pharma, and received travel grant from Vitalaire, PEPS development, Aguettant, Orkyn, Elivie, and Adelia Medical. B.M, E.C., M.D., F.C.D., N.V, C.T., C.L., Y.W., and M.V. declare absence of commercial or financial relationships that could be construed as potential conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"50"}}